Exposure to immunosuppressant tied to cancer risk after liver transplant
Findings from a multicentre study suggest strategies are needed to minimise exposure and screen patients post-transplant
Higher cumulative exposure to tacrolimus in the first year after liver transplant has been linked to a higher risk for de novo malignancies and recurrent liver cancer in a case-control study.
Researchers at 16 transplant centres in Spain studied nearly 3000 patients who underwent liver transplantation between 2010 and 2015 and were treated with tacrolimus, including 491 (19.7%) who developed cancer during a median follow-up of 65 months.
Incidence rates were 3.5/100 person-years for all
